Skip to content

Vaxcyte, Inc. PCVX Operating Lease Liability Payments Due

Operating Lease Liability Payments Due at other companies

Moderna logo
ModernaMRNA
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Operating income-$345.9M-91.3%
Net income-$320.6M-128%
EPS (diluted)-$2.30-121%

Balance sheet

See full
Cash & equivalents$262.3M-24.7%
Total debt$116.3M+33.5%
Total equity$3.0B-6.4%
Total assets$3.3B-0.9%

Cash flow

See full
Operating cash flow-$280.6M-68.8%
CapEx$2.1M-61.2%
Free cash flow-$282.7M-64.7%

Valuation

See full
Market cap$7.43B+72.0%
Enterprise value$7.28B+78.6%

Returns & leverage

See full
Return on equity-30.6%+37.9pp
Debt / equity0.0×
Current ratio7.5×-10.2×

Where this comes from

Reported directly by Vaxcyte, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue.

The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vaxcyte, Inc.'s operating lease liability payments due.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vaxcyte, Inc.'s operating lease liability payments due?
Vaxcyte, Inc. (PCVX) reported operating lease liability payments due of $161.12M in Q1 2026.
How has Vaxcyte, Inc.'s operating lease liability payments due changed year-over-year?
Vaxcyte, Inc.'s operating lease liability payments due increased by 30.1% year-over-year, from $123.8M to $161.12M.
What does operating lease liability payments due mean?
This represents the total future cash outflows required to satisfy operating lease agreements. It reflects the company's reliance on leased assets rather than owned assets to conduct business operations. Monitoring this helps evaluate the company's operational leverage and fixed cost structure.